Santhera Pharmaceuticals’ Post

Today, Santhera announced financing taking the Company to cash flow break-even! – “We are very pleased to have achieved significant financing goals for Santhera and our shareholders through these initiatives. The new financing is non-dilutive to shareholders, the royalty monetization is partial and capped, leaving upside potential to Santhera, and the debt repayment schedule aligns well with our growth expectations,” said Andrew Smith, Chief Financial Officer of Santhera. “Importantly, it addresses our near-term debt obligations and provides us with sufficient funding to drive market launches and growth of AGAMREE in Europe and to pursue additional development programs for AGAMREE.” Read our press release at https://bit.ly/3Rx4Qpg #Santhera #theirfutureourfocus